226 related articles for article (PubMed ID: 30926646)
21. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
22. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
[TBL] [Abstract][Full Text] [Related]
23. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
[TBL] [Abstract][Full Text] [Related]
24. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study.
Fielding SL; Flower MA; Ackery D; Kemshead JT; Lashford LS; Lewis I
Eur J Nucl Med; 1991; 18(5):308-16. PubMed ID: 1936038
[TBL] [Abstract][Full Text] [Related]
25. PET/CT imaging of the diapeutic alkylphosphocholine analog
Hall LT; Titz B; Robins HI; Bednarz BP; Perlman SB; Weichert JP; Kuo JS
Am J Nucl Med Mol Imaging; 2017; 7(4):157-166. PubMed ID: 28913154
[TBL] [Abstract][Full Text] [Related]
26. A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies.
Lubner SJ; Mullvain J; Perlman S; Pishvaian M; Mortimer J; Oliver K; Heideman J; Hall L; Weichert J; Liu G
Cancer Invest; 2015; 33(10):483-9. PubMed ID: 26536061
[TBL] [Abstract][Full Text] [Related]
27. In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome.
Shalaby-Rana E; Majd M; Andrich MP; Movassaghi N
Clin Nucl Med; 1997 May; 22(5):315-9. PubMed ID: 9152532
[TBL] [Abstract][Full Text] [Related]
28. Pinhole imaging of 131I-metaiodobenzylguanidine (131I-MIBG) in an animal model of neuroblastoma.
Accorsi R; Morowitz MJ; Charron M; Maris JM
Pediatr Radiol; 2003 Oct; 33(10):688-92. PubMed ID: 12908090
[TBL] [Abstract][Full Text] [Related]
29. Enhanced Radiosensitivity in Solid Tumors using a Tumor-selective Alkyl Phospholipid Ether Analog.
Elsaid MY; Shahi A; Wang AR; Baiu DC; Li C; Werner LR; Singhal S; Hall LT; Weichert JP; Armstrong EA; Bednarz BP; Harari PM; Iyer G; Otto M
Mol Cancer Ther; 2018 Nov; 17(11):2320-2328. PubMed ID: 30108133
[TBL] [Abstract][Full Text] [Related]
30. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry.
Prideaux AR; Song H; Hobbs RF; He B; Frey EC; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2007 Jun; 48(6):1008-16. PubMed ID: 17504874
[TBL] [Abstract][Full Text] [Related]
31. Nuclear Medicine in Pediatric and Adolescent Tumors.
Kiratli PÖ; Tuncel M; Bar-Sever Z
Semin Nucl Med; 2016 Jul; 46(4):308-23. PubMed ID: 27237441
[TBL] [Abstract][Full Text] [Related]
32. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
33. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
34. Radiolabeled (4-Fluoro-3-Iodobenzyl)Guanidine Improves Imaging and Targeted Radionuclide Therapy of Norepinephrine Transporter-Expressing Tumors.
Yamaguchi A; Hanaoka H; Higuchi T; Tsushima Y
J Nucl Med; 2018 May; 59(5):815-821. PubMed ID: 29217738
[No Abstract] [Full Text] [Related]
35. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
Palm S; Enmon RM; Matei C; Kolbert KS; Xu S; Zanzonico PB; Finn RL; Koutcher JA; Larson SM; Sgouros G
J Nucl Med; 2003 Jul; 44(7):1148-55. PubMed ID: 12843231
[TBL] [Abstract][Full Text] [Related]
36. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
[TBL] [Abstract][Full Text] [Related]
37. Iodine-131 and Iodine-131-Meta-iodobenzylguanidine Dosimetry in Cancer Therapy.
Flux G; Leek F; Gape P; Gear J; Taprogge J
Semin Nucl Med; 2022 Mar; 52(2):167-177. PubMed ID: 34961618
[TBL] [Abstract][Full Text] [Related]
38. Clinical applications of dosimetry for mIBG therapy.
Flux GD; Chittenden SJ; Saran F; Gaze MN
Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):116-25. PubMed ID: 21386786
[TBL] [Abstract][Full Text] [Related]
39. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
40. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG.
Brogsitter C; Pinkert J; Bredow J; Kittner T; Kotzerke J
J Nucl Med; 2005 Dec; 46(12):2112-6. PubMed ID: 16330578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
